Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

University of Toronto

$105,000.00

NOD1/2 Mediated Control of Innate and Adaptive T cell function during Chronic Colitis

EF 2012-13

Résumé
Inflammatory bowel disease is a set of diseases that are defined by chronic inflammation of the gastrointestinal tract. Currently, Canada has one of the highest incidences of inflammatory bowel disease worldwide with over 200,000 sufferers and an annual health system cost of over $753 million. Symptoms of inflammatory bowel disease include diarrhea, rectal bleeding, vomiting and low energy levels. Once diagnosed with inflammatory bowel disease, sufferers often have a decreased quality of life, with negative impacts on personal lifestyle, intimacy and career choice. While treatments can decrease the severity of the symptoms, there is no known cure, other than surgical removal of the colon. Recent advances in research have shown that people with a mutation to the NOD2 gene have an increased susceptibility to inflammatory bowel disease; however, it is unknown how NOD2 contributes to the disease progression. Alternatively, activation of invariant natural killer T cells (iNKT cells), a fast acting immune system cell, has recently been shown to confer protection against inflammatory bowel disease in mice. In my research I plan to investigate the consequence of NOD2 mutation on iNKT cell activation and the onset of inflammatory bowel disease. This research will provide a clearer understanding of the mechanisms involved in the onset of inflammatory bowel disease and may lead to the discovery of an alternative cure.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
283815
Name
Escalante Nichole K
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
NOD1/2 Mediated Control of Innate and Adaptive T cell function during Chronic Colitis
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Crohn'S Disease; Immunoregulation; Immunotherapy; Inflammatory Bowel Diesease; Inkt Cells; Mucosal Immunology; Nod1/2; T Cells
Abstract
Inflammatory bowel disease is a set of diseases that are defined by chronic inflammation of the gastrointestinal tract. Currently, Canada has one of the highest incidences of inflammatory bowel disease worldwide with over 200,000 sufferers and an annual health system cost of over $753 million. Symptoms of inflammatory bowel disease include diarrhea, rectal bleeding, vomiting and low energy levels. Once diagnosed with inflammatory bowel disease, sufferers often have a decreased quality of life, with negative impacts on personal lifestyle, intimacy and career choice. While treatments can decrease the severity of the symptoms, there is no known cure, other than surgical removal of the colon. Recent advances in research have shown that people with a mutation to the NOD2 gene have an increased susceptibility to inflammatory bowel disease; however, it is unknown how NOD2 contributes to the disease progression. Alternatively, activation of invariant natural killer T cells (iNKT cells), a fast acting immune system cell, has recently been shown to confer protection against inflammatory bowel disease in mice. In my research I plan to investigate the consequence of NOD2 mutation on iNKT cell activation and the onset of inflammatory bowel disease. This research will provide a clearer understanding of the mechanisms involved in the onset of inflammatory bowel disease and may lead to the discovery of an alternative cure.
Competitiondate
201210
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Escalante, Nichole K
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~